ADC Therapeutics to Host Webcast Highlighting its ADC Platform and Solid Tumor Pipeline on February 8, 2022
20 Januar 2022 - 1:15PM
Business Wire
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage
biotechnology company improving the lives of those affected by
cancer with its next-generation, targeted antibody drug conjugates
(ADCs) for patients with hematologic malignancies and solid tumors,
today announced it will host a webcast highlighting its ADC
platform and solid tumor pipeline on Tuesday, February 8, from 9:00
to 11:00 a.m. ET.
Chris Martin, PhD, Chief Executive Officer, Patrick van Berkel,
PhD, Senior Vice President of Research & Development, and
Joseph Camardo, MD, Chief Medical Officer, will provide insight
into the company’s proprietary ADC platform technology and a deep
dive into the company’s promising pipeline of programs for the
treatment of various solid tumors.
A live webcast will be available via the Events &
Presentations page in the Investors section of ADC Therapeutics’
website, ir.adctherapeutics.com. A replay of the webcast will be
available for approximately 30 days.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage
biotechnology company improving the lives of those affected by
cancer with its next-generation, targeted antibody drug conjugates
(ADCs). The Company is advancing its proprietary PBD-based ADC
technology to transform the treatment paradigm for patients with
hematologic malignancies and solid tumors.
ADC Therapeutics’ CD19-directed ADC ZYNLONTA® (loncastuximab
tesirine-lpyl) is approved by the FDA for the treatment of relapsed
or refractory diffuse large B-cell lymphoma after two or more lines
of systemic therapy. ZYNLONTA is also in development in combination
with other agents. Cami (camidanlumab tesirine) is being evaluated
in a pivotal Phase 2 clinical trial for relapsed or refractory
Hodgkin lymphoma and in a Phase 1b clinical trial for various
advanced solid tumors. In addition to ZYNLONTA and Cami, ADC
Therapeutics has multiple ADCs in ongoing clinical and preclinical
development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and
has operations in London, the San Francisco Bay Area and New
Jersey. For more information, please visit
https://adctherapeutics.com/ and follow the Company on Twitter and
LinkedIn.
ZYNLONTA® is a registered trademark of ADC Therapeutics SA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220120005083/en/
Investors Eugenia Litz ADC Therapeutics
Eugenia.Litz@adctherapeutics.com +44 7879 627205
Amanda Hamilton ADC Therapeutics
amanda.hamilton@adctherapeutics.com +1 917-288-7023
EU Media Alexandre Müller Dynamics Group amu@dynamicsgroup.ch
+41 (0) 43 268 3231
USA Media Mary Ann Ondish ADC Therapeutics
maryann.ondish@adctherapeutics.com Tel.: +1 914-552-4625
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
Von Apr 2023 bis Apr 2024